LUPIN
Lupin Limited (LUPIN) Stock Analysis
Lupin Limited is a major Indian pharmaceutical company developing and manufacturing generics, complex inhalation products, and APIs for global markets. It has a broad portfolio in cardiovascular, anti-infective, and specialty therapies with facilities approved by stringent regulators. The company invests in R&D and complex generics. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹1,956.50
-3.68% 1W | -1.10% 52W
Market Cap
89.5k CR
P/E Ratio
16.2
52W High
₹2529.5
52W Low
₹1900
Div. Yield
0.93%
Beta
0.2
50 DMA
₹2161.1
200 DMA
₹2263.3
Profit Margin
18.5%
Inst. Own.
34.9%
📊 ANALYZING TREND
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,814 | 5,039 | 5,197 | 4,961 | 5,600 | 5,673 | 5,768 | 5,667 | 6,268 | 7,048 | 7,168 | 7,475 | 8,277 |
| Expenses | 3,958 | 4,121 | 4,159 | 3,964 | 4,359 | 4,332 | 4,412 | 4,346 | 4,541 | 4,706 | 4,906 | 4,989 | 5,827 |
| Operating Profit | 856 | 918 | 1,038 | 997 | 1,241 | 1,340 | 1,356 | 1,321 | 1,727 | 2,341 | 2,262 | 2,486 | 2,450 |
| OPM % | 18% | 18% | 20% | 20% | 22% | 24% | 24% | 23% | 28% | 33% | 32% | 33% | 30% |
| Other Income | 23 | 40 | 29 | 29 | 68 | 42 | 54 | 57 | 79 | 90 | -312 | 9 | 130 |
| Interest | 86 | 81 | 74 | 71 | 68 | 71 | 67 | 89 | 92 | 108 | 115 | 120 | 110 |
| Depreciation | 235 | 248 | 257 | 457 | 248 | 257 | 271 | 393 | 299 | 317 | 313 | 447 | 453 |
| Profit before tax | 559 | 630 | 736 | 498 | 993 | 1,055 | 1,071 | 896 | 1,416 | 2,007 | 1,522 | 1,928 | 2,017 |
| Tax % | 19% | 21% | 16% | 26% | 19% | 19% | 20% | 13% | 14% | 26% | 22% | 24% | 30% |
| Net Profit | 453 | 495 | 619 | 368 | 806 | 859 | 859 | 782 | 1,221 | 1,485 | 1,181 | 1,469 | 1,417 |
| EPS in Rs | 9.94 | 10.76 | 13.47 | 7.89 | 17.58 | 18.69 | 18.74 | 16.92 | 26.69 | 32.36 | 25.73 | 31.94 | 30.95 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12,770 | 14,256 | 17,367 | 15,797 | 14,665 | 15,375 | 15,163 | 16,405 | 16,642 | 20,011 | 22,708 | 27,958 | 29,967 |
| Expenses | 9,146 | 10,564 | 12,865 | 12,649 | 12,104 | 13,020 | 12,596 | 16,187 | 14,921 | 16,211 | 17,430 | 19,798 | 20,428 |
| Operating Profit | 3,624 | 3,691 | 4,502 | 3,148 | 2,561 | 2,355 | 2,567 | 219 | 1,721 | 3,800 | 5,278 | 8,160 | 9,538 |
| OPM % | 28% | 26% | 26% | 20% | 17% | 15% | 17% | 1.3% | 10% | 19% | 23% | 29% | 32% |
| Other Income | 235 | 184 | 106 | -1,310 | 91 | -134 | 138 | 210 | 151 | 131 | 202 | 523 | -82 |
| Interest | 10 | 59 | 153 | 204 | 302 | 363 | 141 | 143 | 274 | 312 | 295 | 434 | 452 |
| Depreciation | 435 | 487 | 912 | 1,086 | 846 | 970 | 887 | 1,659 | 881 | 1,197 | 1,169 | 1,376 | 1,529 |
| Profit before tax | 3,415 | 3,329 | 3,543 | 547 | 1,503 | 887 | 1,676 | -1,372 | 716 | 2,422 | 4,015 | 6,873 | 7,474 |
| Tax % | 28% | 32% | 28% | 53% | 59% | 130% | 27% | 10% | 38% | 20% | 18% | 22% | |
| Net Profit | 2,444 | 2,270 | 2,565 | 258 | 615 | -270 | 1,228 | -1,528 | 448 | 1,936 | 3,306 | 5,355 | 5,551 |
| EPS in Rs | 53.47 | 50.17 | 56.63 | 5.56 | 13.40 | -5.95 | 26.81 | -33.62 | 9.45 | 42.01 | 71.88 | 116.65 | 120.98 |
| Dividend Payout % | 14% | 15% | 13% | 90% | 37% | -101% | 24% | -12% | 42% | 19% | 17% | 15% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 19.0% | 13.0% | 7.0% |
| Profit CAGR | 140.0% | 37.0% | 10.0% |
Shareholding Pattern
Promoters46.90%
FIIs21.25%
DIIs25.55%
Public6.28%
Promoters46.89%
FIIs20.50%
DIIs26.56%
Public6.06%
Promoters46.89%
FIIs21.50%
DIIs25.58%
Public6.04%
Promoters46.85%
FIIs21.70%
DIIs25.32%
Public6.13%
Promoters46.85%
FIIs22.42%
DIIs24.65%
Public6.08%
Promoters47.08%
FIIs13.32%
DIIs28.92%
Public10.39%
Promoters47.01%
FIIs18.29%
DIIs27.76%
Public6.93%
Promoters46.91%
FIIs21.46%
DIIs25.41%
Public6.21%
Promoters46.85%
FIIs21.70%
DIIs25.32%
Public6.13%
Promoters46.85%
FIIs22.42%
DIIs24.65%
Public6.08%
LUPIN
Holdings Analysis
Key strengths & risk signals
65
Overall
85
Fundamental
45
Technical
Risks (4)
NEGLIGIBLE DIVIDEND! 0.93% yield - little to no income.
WEAK POSITION! Current price (1956.5) is below both moving averages.
WEAK! Trading at 9.0% of 52W range - near yearly lows.
NEGATIVE MOMENTUM! Price declined across timeframes - down 3.7% (1 week), 6.8% (1 month), 21.6% (3 months).
Strengths (3)
UNDERVALUED! PEG of 0.12 indicates stock is cheap relative to growth.
OVERSOLD! RSI at 29.0 - potential bounce opportunity.
LOW VOLATILITY! Beta of 0.20 - stable stock, less market risk.
Fundamental & Technical Analysis
65Overall
85Fundamental
45Technical
Fundamental Breakdown
Growth Quality
28/30
Revenue CAGR: 19.1% (VERY GOOD, 13/15). Profit CAGR: 131.5% (EXCELLENT, 15/15).
Profit Margin
6/10
GOOD EFFICIENCY! 18.5% profit margin - above average profitability.
PEG Valuation
10/10
UNDERVALUED! PEG of 0.12 indicates stock is cheap relative to growth.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.93% yield - little to no income.
Debt to Equity
8/10
LOW DEBT! D/E of 0.32 - strong balance sheet.
Public Holding
20/20
VERY LESS PUBLIC HOLDING! 9.62% public ownership - strong promoter/institutional control.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
3/10
BEARISH TREND! 50-day average (2161.1) is below 200-day average (2263.3) - negative signal.
Price Position
2/10
WEAK POSITION! Current price (1956.5) is below both moving averages.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
3/10
WEAK YEAR! Stock declined 1.1% in the last year.
Volume Sentiment
15/30
BEARISH SENTIMENT! In last 30 days: 10 up days, 20 down days. Avg volume on up days: 650,219 vs down days: 753,999. Ratio: 0.86x
RSI
5/5
OVERSOLD! RSI at 29.0 - potential bounce opportunity.
52W Range
1/5
WEAK! Trading at 9.0% of 52W range - near yearly lows.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 3.7% (1 week), 6.8% (1 month), 21.6% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.20 - stable stock, less market risk.
LUPIN
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-12 | Concall PDF | |
| Q4FY262026-05-14 | Concall PDF | |
| Q3FY262026-02-17 | Concall PDF | |
| Q2FY262025-11-12 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LUPIN | ₹1,956.50 | 16.2 | 18.5% | 19.1% | 131.5% | -1.1% | 65 | BREAKDOWN | +16.1% | -3.1% | +33.3% | +11.2% |
| AUROPHARMA | ₹1,693.00 | 26.5 | 10.6% | 10.7% | 22.1% | +45.5% | 81 | APPROACHING RESISTANCE | +25.2% | +12.1% | +16.9% | +4.0% |
| MANKIND | ₹2,368.50 | 47.9 | 13.9% | 17.7% | 14.3% | -3.2% | 70 | APPROACHING SUPPORT | +29.6% | +2.5% | +12.9% | +17.1% |
| DRREDDY | ₹1,197.00 | 30.1 | 10.0% | 11.0% | -1.7% | -3.4% | 63 | BREAKOUT | -68.7% | +100.8% | -5.6% | +7.4% |
| CIPLA | ₹1,301.00 | 31.2 | 12.0% | 7.2% | 11.5% | -16.3% | 60 | APPROACHING SUPPORT | -39.2% | +42.3% | +3.5% | +9.5% |
| LAURUSLABS | ₹2,036.60 | 100.7 | 15.0% | 3.8% | 4.0% | +127.9% | 55 | CONSOLIDATING UP | +125.5% | +31.7% | +29.1% | +11.9% |
| ZYDUSLIFE | ₹1,117.50 | 24.9 | 15.8% | 16.5% | 37.0% | +15.9% | 75 | APPROACHING SUPPORT | -35.9% | -26.1% | +20.6% | +4.9% |
| GLENMARK | ₹2,293.00 | 34.6 | 10.1% | 13.5% | 66.1% | +17.7% | 69 | BREAKDOWN | +929.6% | +60.2% | +28.5% | +4.6% |
Data from TradeAlone · Updated daily
LUPIN News
Lupin Limited (lupin) Receives Tentative FDA Approval for Apixaban Oral Suspension2026-09-28Lupin Limited Receives U.S. FDA Approval for Modafinil Tablets2026-09-04Lupin Limited (lupin) Secures U.S. FDA Approval for Pitolisant Tablets2026-08-17Lupin Limited Receives FDA Approval for Sodium Zirconium Cyclosilicate Oral Suspension2026-08-10Lupin Limited (LUPIN) breaks below support, falls 5% intraday2026-08-10Lupin Limited Q1 FY27: Investor Presentation Highlights Strategic Growth and Developments2026-08-07Lupin Limited (lupin) Secures U.S. FDA Approval for Diazepam Injection USP2026-07-31Lupin Limited (lupin) Secures U.S. FDA Approval and Launches Sugammadex Injection2026-07-31Lupin Limited Recognized Among India’s Best Employers in Nation Builders Category2026-07-14Lupin Limited Named Among World’s Most Sustainable Companies in 20262026-07-06Lupin Limited (lupin) Secures EMA Approval for Expanded Pediatric Indication for Namuscla®2026-07-01Lupin Limited Receives Tentative Approval from U.S. FDA for Enzalutamide Tablets2026-06-26Lupin Limited Launches Azilsartan Medoxomil Tablets in U.S.2026-06-17Lupin Limited Collaborates with ERN for Luforbec® Launch in Spain2026-06-08Lupin Limited Receives FDA Approval for Eribulin Mesylate Injection2026-06-03
